Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

Summary

Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.

Conditions

• Antiplatelet Therapy
• Hemorrhagic Infarction

Interventions

DRUG

Early aspirin Therapy

Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.

DRUG

Non-Early aspirin Therapy

Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.

Sponsors & Collaborators

• Shaoxing People's Hospital

  collaborator OTHER

• Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Huzhou Central Hospital

  collaborator OTHER

• The Second Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Jinhua Central Hospital

  collaborator OTHER

• Taizhou Hospital

  collaborator OTHER

• Ningbo Medical Center Lihuili Hospital

  collaborator OTHER_GOV

• Ningbo No.2 Hospital

  collaborator OTHER

• Lishui Country People's Hospital

  collaborator OTHER

• Wenzhou Central Hospital

  collaborator OTHER

• The Fourth Affiliated Hospital of Zhejiang University School of Medicine

  collaborator OTHER

• Shenzhen Second People's Hospital

  collaborator OTHER

• The Affiliated Hospital of Xuzhou Medical University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Principal Investigators

• Min Lou, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-01-01

Primary Completion

2025-12-31

Completion

2026-06-30

Countries

• China

Study Locations